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Background: We wished to estimate the proportion of patients with breast cancer eligible for an exclusive
targeted intraoperative radiotherapy (TARGIT) and to evaluate their survival without local recurrence.
Methods: We undertook a retrospective study examining two cohorts. The first cohort was multicentric (G3S) and
contained 7580 patients. The second cohort was monocentric (cohort 2) comprising 4445 patients. All patients
underwent conservative surgery followed by external radiotherapy for invasive breast cancer (T0–T3, N0–N1)
between 1980 and 2005. Within each cohort, two groups were isolated according to the inclusion criteria of the
TARGIT A study (T group) and RIOP trial (R group).
In the multicentric cohort (G3S) eligible patients for TARGIT A and RIOP trials were T1E and R1E subgroups,
respectively. In cohort number 2, the corresponding subgroups were T2E and R2E. Similarly, non-eligible patients
were T1nE, R1nE and T2nE, and R2nE.
The eligible groups in the TARGIT A study that were not eligible in the RIOP trial (TE–RE) were also studied. The
proportion of patients eligible for TARGIT was calculated according to the criteria of each study. A comparison was
made of the 5-year survival without local or locoregional recurrence between the TE versus TnE, RE versus RnE, and
RE versus (TE–RE) groups.
Results: In G3S and cohort 2, the proportion of patients eligible for TARGIT was, respectively, 53.2% and 33.9%
according the criteria of the TARGIT A study, and 21% and 8% according the criteria of the RIOP trial. Survival
without five-year locoregional recurrence was significantly different between T1E and T1nE groups (97.6% versus
97% [log rank =0.009]), R1E and R1nE groups (98% versus 97.1% [log rank =0.011]), T2E and T2nE groups (96.6%
versus 93.1% [log rank <0. 0001]) and R2E and R2nE groups (98.6% versus 94% [log rank =0.001]). In both cohorts, no
significant difference was found between RE and (TE–RE) groups.
Conclusions: Almost 50% of T0-2 N0 patients could be eligible for TARGIT.
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Breast cancer (BC) is the leading cancer worldwide in
terms of incidence, with 1.38 million new cases diag-
nosed in 2008 (23% of all cancers). It is now the most
frequent cancer in “developed” and “developing” coun-
tries [1]. BC management, therefore, is a major issue
in terms of public health at therapeutic and economic
levels.
Screening by mammography is undertaken in most
developed countries. It has enabled BC to be diagnosed at
an early stage, thereby allowing the possibility of con-
servative surgery. Several studies have shown that in
conservative surgery of an invasive cancer, adjuvant
radiation of the breast and surgical site significantly
increases survival without recurrence and has an im-
pact on overall survival [2].
The correlation between local recurrence and metasta-
sis has also been confirmed for tumors treated at very
limited stages, at which point it is possible to use partial
radiation [3]. However, radiotherapy is not readily avail-
able in many countries. Almost 90% of recurrences of
BC are localized in the same quadrant [4]. Based on this
clinical information and with the objective of making ac-
cess to radiotherapy easier, partial-breast irradiation
methods (e.g., brachytherapy, external radiotherapy, in-
traoperative radiotherapy) have been developed over the
last 20 years.
Here, we describe a retrospective study focusing on
patients undergoing conservative treatment associated
with partial surgery and conventional external radiother-
apy for invasive cancer. We had two main objectives.
First, we wished to estimate the proportion of patients
eligible for exclusive targeted intraoperative radiotherapy
(TARGIT) according to the criteria set by TARGIT A
trial and RIOP (Radiothérapie IntraOPératoire) trial
(RIOP is a trial being carried out in France, coordina-
ted by the Institut René Gauducheau and it is being
conducted under the aegis of the Institut National du
Cancer)[5]. Second, we wished to evaluate and com-
pare survival without local recurrence or locoregional
recurrence among patients eligible and ineligible for
TARGIT according to the criteria of the two trials
mentioned above.
Methods
This was a retrospective study examining two cohorts of
patients who had undergone conservative surgery followed
by external radiotherapy for invasive, non-metastatic and
non-inflammatory BC.
The first cohort was multicentric (cohort G3S) and
comprised 7580 patients treated in 13 French centers
from 1999 to 2008. All of these subjects had undergone
biopsy of a sentinel node with or without axillary dissec-
tion for tumors of stages T0–T2 and N0. Characteristicsof patients with small tumors and results of treatment
are described in a study that will be published shortly
[6]. The second cohort was monocentric (cohort 2). It
consisted of 4445 patients treated at the Institut Paoli
Calmettes (IPC) from 1980 to 2005 by conservative sur-
gery for tumors of stage T0–T3, N0 or N1 with biopsy of
the sentinel node associated or not with axillary dissec-
tion, or alternatively with immediate axillary dissection.
This study was approved by the ethics committee of
the Paoli-Calmettes Institute.
Anatomopathologic information
Anatomopathologic analyses of each resected specimen
defined the size, histologic type and the stage (using the
Scarff–Bloom–Richardson classification [SBR]) of the tu-
mor [7], as well as the presence of peri-tumor vascular
emboli and nodal invasion. Immunohistochemical me-
thods were used to establish the presence of hormone
receptors with estrogens and progesterone at a threshold
of 10%. Data relating to overexpression of the human
epidermal growth factor receptor (HER2) were too re-
cent compared with the period of the study and insuffi-
ciently exhaustive, so they were not used in cohort 2.
The overexpressed status (or otherwise) of HER2 was
defined in 4732 patients of the G3S cohort.
Adjuvant therapies
All patients had undergone external radiotherapy of the
mammary gland, most frequently in conjunction with a
boost to the tumor bed. The systemic treatments that
were proposed were chemotherapy in accordance with
the data of the various centers and hormone therapy for
5 years for hormone-sensitive tumors.
Study groups and parameters studied
Two groups were isolated within each cohort using the
inclusion criteria of the RIOP and TARGIT-A trials.
Each group was divided into two subgroups by separat-
ing patients who were eligible for TARGIT from those
who were not: RIOP trial with subgroups R1E and R1nE
for the G3S cohort; R2E and R2nE for cohort 2 and the
TARGIT A trial with subgroups T1E and T1nE for the
G3S cohort; T2E and T2nE for cohort 2. The subgroup
of patients eligible in the TARGIT A study and not eli-
gible in the RIOP study (TE-RE) were also studied in
each cohort (Figure 1).
In each trial, eligibility criteria were related to pre-
operative clinical, radiologic and histologic data. Patients
eligible for TARGIT according to the TARGIT A study
were aged ≥45 years and had a unifocal lesion of invasive
ductal carcinoma. Three postoperative criteria indica-
ted the need for external irradiation of the mammary
gland: invasive lobular-type histology; an extensive in-
traductal component; unhealthy margins (which also
Figure 1 Groups and sub-groups studied.
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Grade-3, nodal or lymphovascular invasion could lead
to the proposal of external radiation but this decision was
left to the discretion of each center. It was preferable that
the lesion measured 3.5 cm without this criterion impos-
ing the need for adjuvant external radiation. In the present
study, of the 996 randomized patients treated effectively
by TARGIT, 142 patients received complementary exter-
nal radiotherapy without the details of the criterion having
indicated this radiation. We considered the following fac-
tors as eligibility criteria for TARGIT according to the
TARGIT A trial: ≥45 years; unifocal invasive ductal-type
lesion; pN0 with healthy excision margins.The eligibility criteria for TARGIT according to the
RIOP trial were: menopausal patients not carrying a
known mutation in the breast cancer (BRCA)1 or 2
gene; age ≥55 years; tumor size ≤2 cm; a unifocal inva-
sive ductal-type lesion; tumor grade 1 or 2; expression
of hormone receptors; no amplification of HER2 ex-
pression; absence of vascular peri-tumor emboli or clin-
ical nodal invasion. Postoperative nodal invasion, an
extensive intraductal component, unhealthy excision
margins, and failure to comply with the criteria stated
above at the preoperative stage rendered complemen-
tary external radiotherapy necessary. Inclusion criteria
in both studies are summarized in Table 1.
Table 1 Inclusion criteria for TARGIT A and RIOP trials
TARGIT A RIOP
Age (years) ≥45 ≥55
Menopausal status Not required Required
Unifocal tumor Required Required
Histology Invasive ductal carcinoma Invasive ductal carcinoma
Tumor size Suitable for wide local excision (<3.5 cm preferable) ≤2 cm
SBR grade 1 and 2, hormone receptor-positive,
no vascular invasion, HER2
Not required All of these criteria were required
No known BRCA mutation Not required Required
Ziouèche-Mottet et al. BMC Cancer 2014, 14:868 Page 4 of 11
http://www.biomedcentral.com/1471-2407/14/868For each cohort we calculated the proportion of
patients eligible for TARGIT according to the criteria
of each of the trials. Then, we compared the survival
rates without local recurrence or SSRL at 5 years and
7 years of the following groups: RE groups versus RnE
groups; TE groups versus TnE groups; RE groups versus
(TE–RE).
The diagnosis of local recurrence was defined as appear-
ance of a tumorous lesion developed within the treated
breast and confirmed by histologic analyses. Locoregional
recurrence comprised axillary local and nodal recurrence,
supraclavicular and infraclavicular recurrence, or intra-
mammary recurrence. Local recurrence could be identi-
fied in cohort 2. Only locoregional recurrence was known
in the G3S cohort. However, the literature suggests that
nodal recurrences represent a very small number of locor-
egional recurrences. Thus, locoregional recurrence can
be considered to be survival without local recurrence in
almost all cases [8-10].
Statistical analyses
All statistical tests were two-sided. Comparisons were
made using: chi-square tests for percentages; Student’s
t-test for mean values (statistical significance was set at
0.05 for both tests) and log-rank test for survival (statis-
tical significance was set at 0.1). Statistical analyses were
carried out using SPSS v16.0 (SPSS, Armonk, NY, USA).
Results
Population characteristics
In the total population, mean age at the diagnosis was
58 years (median, 58; range, 22–101) for the G3S cohort
and 55.6 years (55; 20–91) years for the IPC cohort. The
mean pathologic size of T1 lesions was 15 mm (median,
13; range, 0.1–9.0) and 19.2 mm (17; 1–125) with 84.8%
(6425/7580) and 67.7% (3010/4445), respectively, in G3S
and IPC cohorts. Within this population, all patients
had undergone conservative surgery associated with ax-
illary lymph-node dissection. A total of 36.7% (2784/
7580) and 43.6% (1938/4445) of patients received adju-
vant chemotherapy, and 84.3% (6373/7556) and 54.6%(2417/4422) of patients underwent adjuvant hormonal
therapy for the G3S cohort and cohort 2, respectively.
All patients received adjuvant radiotherapy of the mam-
mary gland at 50 Gy, most often with a boost of 16 Gy
to the tumor bed.
Characteristics of the eligible patients in the TARGIT
A and RIOP studies of each cohort are shown in Table 2.
There was a significant difference between the two co-
horts in terms of the following characteristics: age; tu-
mor size >20 mm; RH−; pN+; grade; vascular peri-tumor
emboli (p < 0.0001). Also, a population showed more un-
favorable characteristics in the IPC cohort (p < 0.0001).
Table 3 shows that, in each cohort, eligible patients in
the RIOP study (R1E and R2E) had significantly different
characteristics from the eligible patients in the TARGIT
A study and non-eligible patients in the RIOP study
(TE–RE).
Proportion of eligible patients, survival without local
recurrence and without locoregional recurrence
In the G3S cohort, the proportion of patients eligible for
TARGIT was 21% (1593/7580) and 53.2% (4036/7580),
respectively, for the criteria of the RIOP and TARGIT A
studies (Table 2). Survival without locoregional recur-
rence after 5 years and 7 years was 98% and 97.1%, re-
spectively, for the R1E group versus 97.1% and 94.8% for
the R1nE group; 97.6% and 96.4% for the T1E group versus
97% and 94.2% for the T1nE group. There was a significant
difference in survival without locoregional recurrence be-
tween T1E and T1nE groups (log rank =0.009) and be-
tween the R1E and R1nE groups (log rank =0.011). There
was no significant difference between the R1E and
(T1E–R1E) groups (log rank =0.125) (Table 4).
In the entire G3S cohort, locoregional recurrences were
significantly more frequent in the case of HER2 over-
expression (log rank =0.009). Study of subpopulations
showed that the eligible patients in TARGIT-A and RIOP
studies with tumors overexpressing HER2 did not indicate
locoregional recurrence significantly more frequently than
that in patients without HER2 overexpression. Conversely,
among non-eligible patients with HER2 overexpression,
Table 2 Characteristics of patients eligible for RIOP and TARGIT A trials of the G3S (R1E and T1E), cohort 2(R2E and
T2E) cohorts and of the patients included in the TARGIT A trial, TARGIT arm
COHORT G3S COHORT 2 TARGIT A,
TARGIT ARMR1E T1E R2E T2E
n 1593/7580 (21%) 4036/7580 (53.2%) 356/4445 (8%) 1509/4445 (33.9%) 996/1113 (89.5%)
Age
< 45 years 0 1813 (30.3%) 0/356 (0%) 0/1509 (0%) 17/1113 (2%)
45-54 years 0 1216 (20.3%) 0/356 (0%) 459/1509 (30.4%) 212/1113 (19%)
≥55 years 1593 (100%) 2958 (49.4%) 356/356 (100%) 1050/1509 (69.6%) 884/1113 (80%)
Tumor size
≤20 mm 1593/1593 (100%) 3674/4036 (91%) 356/356 (100%) 1185/1508 (78.6%) 912/1056 (86%)
>20 mm 0/1593 (0%) 362/4036 (9%) 0/356 (0%) 323/1508 (21.2%) 144/1056 (14%)
Histology
Ductal 1391/1593 (87.3%) 3596/4036 (89.1%) 356/356 (100%) 1509/1509 (100%) 1012/1070 (95%)
Lobular 0/1593 (0%) 0/4036 (0%) 0/356 (0%) 0/1509 (0%) 47/1070 (4%)
Mixed 0/1593 (0%) 0/4036 (0%) 0/356 (0%) 0/1509 (0%) 32/1070 (3%)
Colloids, ductal medullary 202/1593 (12.7%) 440/4036 (10.9%) 0/356 (0%) 0/1509 (0%)
Grade
1 931/1593 (58.4%) 1775/3988 (44%) 211/356 (59.3%) 604/1465 (41.2%) 341/1040 (33%)
2 662/1593 (41.6%) 1582/3988 (39.2%) 145/356 (40.7%) 620/1465 (42.3%) 540/1040 (52%)
3 0/1593 (0%) 631/3988 (15.6%) 0/356 (0%) 241/1465 (16.5%) 159/1040 (15%)
pN
0 1593/1593 (100%) 4036/4036 (100%) 356/356 (100%) 1509/1509 (100%) 866/1059 (82%)
1 -3 0/1593 (0%) 0/4036 (0%) 0/356 (0%) 0/1509 (0%) 155/1059 (15%)
>3 0/1593 (0%) 0/4036 (0%) 0/356 (0%) 0/1509 (0%) 54/1059 (4%)
RH
+ 1593/1593 (100%) 3537/4036 (87.6%) 356/356 (100%) 851/1499 (56.8%) 962/1063 (90%)
- 0/1593 (0%) 499/4036 (12.4%) 0/356 (0%) 648/1499 (43.2%) 101/1063 (10%)
EVPT
Absent 1593/1593 (100%) 3056/3389 (90.2%) 356/356 (100%) 1081/1391 (77.7%) 881/1022 (86%)
Present 0/1593 (0%) 333/3389 (9.8%) 0/356 (0%) 310/1391 (22.3%) 141/1022 (14%)
Excision limits
Healthy 1593/1593 (100%) 4036/4036 (100%) 356/356 (100%) 1509/1509 (100%) 970/1072 (90.5%)
Unhealthy 0/1593 (0%) 0/4036 (0%) 0/356 (0%) 0/1509 (0%) 102/1072 (9.5%)
Multifocality
No 1593/1593 (100%) 4036/4036 (100%) 356/356 (100%) 1509/1509 (100%)
Yes 0/1593 (0%) 0/4036 (0%) 0/356 (0%) 0/1509 (0%)
Chemotherapy
No 1387/1469 (94.4%) 802/3834 (20.9%) 317/356 (89%) 1146/1509 (76%) 997/1113 (90%)
Yes 82/1469 (5.6%) 3032/3834 (79.1%) 39/356 (11%) 363/1509 (24%) 116/1113 (10%)
Hormonal therapy
Yes 1426/1589 (89.7%) 3290/4026 (81.7%) 356/356 (100%) 851/1499 (56.8%) 727/1113 (65%)
No 163/1589 (10.3%) 736/4026 (18.3%) 0/356 (0%) 648/1499 (43.2%) 386/1113 (35%)
Radiothery boost to tumor bed
Yes 318/355 (89.6%) 1316/1461 (90%)
No 37/355 (10.4%) 145/1461 (10%)
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Table 2 Characteristics of patients eligible for RIOP and TARGIT A trials of the G3S (R1E and T1E), cohort 2(R2E and
T2E) cohorts and of the patients included in the TARGIT A trial, TARGIT arm (Continued)
Boost dose
<20Gy 305/313 (97.4%) 1156/1298 (89%)
≥20Gy 8/313 (2.6%) 142/1298 (11%)
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greater compared with patients without HER2 overexpres-
sion (Figure 2).
In the IPC cohort, the proportion of patients eligible
for TARGIT was 8% (356/4445) and 33.9% (1509/4445),
respectively, for the criteria of the RIOP and TARGIT A
trials. Survival without local recurrence after 5 years and
7 years was 98.6% and 97.8%, respectively, for the R2E
group versus 94% and 90.8% for the R2nE group, and
96.6% and 94.1% for the T2E group versus 93.1% and
89.8% for the T2nE group. There was a significant diffe-
rence in survival without local recurrence between T2E
and T2nE groups (log rank =0.0001) and between R2E
and R2nE groups (log rank =0.001). There was no signifi-
cant difference between the R2E and T2E–R2E groups
(log rank =0.084) (Table 5).
Discussion
Standard treatment of early-stage BC is based on conser-
vative surgery followed by radiotherapy. This regimen
leads to an increase in survival without recurrence, and
in an increase in overall survival if adjuvant radiation is
used [2]. Classical adjuvant radiation consists of radia-
tion of the mammary gland followed by a boost to the
tumor bed. Depending on the fractionation, this radi-
ation can continue from 3 weeks to 6.5 weeks. Radiothe-
rapy is not available universally (especially in developing
countries). Hence, the need to manage patient comfort
(not to mention economic considerations), partial and ac-
celerated breast irradiation methods (e.g., brachytherapy,
external radiotherapy, intraoperative radiotherapy) have
been developed. A reduction in the time between sur-
gery and radiotherapy, and an increase in the dose of
equivalent radiation are also possible methods. In ad-
dition, radiation (e.g., TARGIT) given during the surgical
procedure also seems to act favorably on the tumoral
microenvironment [4].
In selected patients, these methods result in a reduction
in the volumes treated and duration of radiation with-
out a reduction in survival. In a recent non-inferiority
phase-3 randomized trial, Vaidya et al. showed the ab-
sence of a significant difference in terms of local recur-
rence ≤4 years in 2232 randomized patients between
external radiotherapy and intraoperative radiotherapy
with 50-kV intrabeam photons [5]. Updating of this
series has confirmed the efficacy of this treatment over5 years for patients who have received TARGIT at the
time of the initial surgery and not at the time of subse-
quent treatment [11].
The criteria for inclusion in the TARGIT A trial were
deliberately broad to encourage physicians to take part
in the trial, giving them freedom in the choice of inclu-
sion criteria and possible complement of external radio-
therapy. Nevertheless, results showed homogeneity in
the characteristics of patients included suggesting, ac-
cording to Vaidya et al., conservatism among the phy-
sicians participating in that study. Other methods of
accelerated partial-breast irradiation using brachythe-
rapy and external radiotherapy for early breast cancer
(ELIOT) have confirmed the safety of this type of radi-
ation [12-14]. The difference in the proportion of sub-
jects eligible for TARGIT observed between G3S and
IPC cohorts (21% and 8% according to the criteria of
the RIOP trial; 53% and 34% according to those of the
TARGIT A trial, respectively) can be explained by the
significantly greater number of patients with unfavor-
able tumor characteristics in the IPC cohort. In the
G3S cohort, survival without locoregional recurrence at
5 years was 98% and 97.6%, respectively, for patients
eligible for TARGIT according to the criteria of the
RIOP and TARGIT A trials. In the IPC cohort, survival
without local recurrence at 5 years was 98.6% and 96.6%,
respectively, for the two groups. Therefore, we would ex-
pect comparable values for local recurrence if the patients
had been treated effectively by TARGIT.
Although significant, the difference in 5-year locore-
gional recurrence between T1E and T1nE (97.6% versus
97%) was small in absolute terms (0.6%). However, the
number of patients still exposed to the risk at 5 years is
acceptable (1921/4031 = 46.6% and 1800/3540 = 50.8%,
respectively, in T1E and T1NE subgroups).
Wide heterogeneity was present with respect to the
indications and procedures of the different treatments.
Eligibility criteria for the RIOP trial were much stricter
than those of the TARGIT A trial. This difference was
why we compared survival without local recurrence or
locoregional recurrence of patient group eligible for
the RIOP trial with the patients eligible for the TARGIT
A trial but not eligible for the RIOP trial (RE versus
TE-RE): in the two cohorts we observed no significant
difference between these groups in terms of survival
without local or locoregional recurrence. These results,
Table 3 Comparison of patients of cohorts G3S (R1E) and cohort 2 (R2E) eligible for the RIOP trial with patients
eligible for the TARGIT A study and not eligible for RIOP (TE-RE)
G3S COHORT p COHORT 2 P
R1E T1E-R1E R2E T2E-R2E
n 1593/7580 (21%) 2443/7580 (32.2%) 356/4445 (8%) 1153/4445 (25.9%)
Age p < 0.0001
< 45 years 0 0 0/356 (0%) 0/1509 (0%)
45-54 years 0 1248 (51.1%) 0/356 (0%) 459/1153 (39.8%)
≥55 years 1593 (100%) 1195 (48.9%) 356/356 (100%) 694/1153 (60.2%)
Tumor size p < 0.0001 p < 0.0001
≤20 mm 1593/1593 (100%) 2081/2443 (85.2%) 356/356 (100%) 829/1152 (72%)
>20 mm 0/1593 (0%) 362/2443 (14.8%) 0/356 (0%) 323/1152 (28%)
Histology p = 0.002
Ductal 1391/1593 (87.3%) 2205/2443 (90.3%) 356/356 (100%) 1153/1153 (100%)
Lobular 0/1593 (0%) 0/2443 (0%) 0/356 (0%) 0/1153 (0%)
Mixed 0/1593 (0%) 0/2443 (0%) 0/356 (0%) 0/1153 (0%)
Colloids, ductal medullary 202/1593 (12.7%) 238/2443 (9.7%) 0/356 (0%) 0/1509 (0%)
Grade p < 0.0001 p < 0.0001
1 931/1593 (58.4%) 844/2395 (34.5%) 211/356 (59.3%) 393/1109 (35.4%)
2 662/1593 (41.6%) 920/2395 (37.7%) 145/356 (40.7%) 475/1109 (42.8%)
3 0/1593 (0%) 631/2395 (25.8%) 0/356 (0%) 241/1109 (21.7%)
pN
0 1593/1593 (100%) 2443/2443 (100%) 356/356 (100%) 1153/1153 (100%)
1 -3 0/1593 (0%) 0/2443 (0%) 0/356 (0%) 0/1153 (0%)
>3 0/1593 (0%) 0/2443 (0%) 0/356 (0%) 0/1153 (0%)
RH p < 0.0001 p < 0.0001
+ 1593/1593 (100%) 499/2443 (20.4%) 356/356 (100%) 495/1143 (43.3%)
- 0/1593 (0%) 1944/2433 (79.6%) 0/356 (0%) 648/1143 (56.7%)
EVPT p < 0.0001 p < 0.0001
Absent 1593/1593 (100%) 333/1796 (18.5%) 356/356 (100%) 725/1035 (70%)
Present 0/1593 (0%) 1463/1796 (81.5%) 0/356 (0%) 310/1035 (30%)
Excision limits
Healthy 1593/1593 (100%) 2443/2443 (100%) 356/356 (100%) 1153/1153 (100%)
Unhealthy 0/1593 (0%) 0/2443 (0%) 0/356 (0%) 0/1153 (0%)
Multifocality
No 1593/1593 (100%) 2443/2443 (100%) 356/356 (100%) 1153/1153 (100%)
Yes 0/1593 (0%) 0/2443 (0%) 0/356 (0%) 0/1153 (0%)
Chemotherapy p < 0.0001 p < 0.0001
No 1387/1469 (94.4%) 720/2065 (20.4%) 317/356 (89%) 829/1153 (71.9%)
Yes 82/1469 (5.6%) 1645/2065 (79.6%) 39/356 (11%) 324/1153 (28.1%)
HT p < 0.0001 p < 0.0001
Yes 1426/1589 (89.7%) 1864/2437 (76.5%) 356/356 (100%) 495/1143 (43.3%)
No 163/1589 (10.3%) 573/2437 (23.5%) 0/356 (0%) 648/1143 (56.7%)
Radiothery boost to tumor bed NS
Yes 318/355 (89.6%) 998/1106 (90.2%)
No 37/355 (10.4%) 108/1106 (9.2%)
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Table 3 Comparison of patients of cohorts G3S (R1E) and cohort 2 (R2E) eligible for the RIOP trial with patients
eligible for the TARGIT A study and not eligible for RIOP (TE-RE) (Continued)
Boost dose p < 0.0001
<20Gy 305/313 (97.4%) 851/985 (86.4%)
≥20Gy 8/313 (2.6%) 134/985 (13.6%)
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teria for TARGIT (which were very restrictive in the
RIOP trial). Magnetic resonance imaging (MRI) of the
breast was not indispensable for inclusion in the pre-
sent study. Nevertheless, one must question the value
of MRI for disqualifying patients with bifocal or multi-
focal tumors.
HER2 overexpression has been reported to be an ag-
gravating factor for local recurrence, though its value as
a factor independent of other criteria (age, emboli, HRs)
is controversial [15,16]. In our study, HER2 overexpres-
sion did not aggravate the risk of local recurrence among
eligible patients and, in consequence, could not be a factor
for exclusion from treatment by TARGIT.
Predictive scores for the risk of local recurrence have
been validated in the literature and could be tools for
assisting patient selection. In a study by Sanghani et al.,
significant factors for local recurrence were established
by proposing a model starting with patients treated in
nine randomized trials. The most significant factors wereTable 4 Comparison of survival without locoregional
recurrence of the G3S cohort
R1E R1nE T1E T1nE T1E-R1E
Number 1589 5982 4031 3540 2442
3 years % 99.4% 98.3% 98.9% 98.2% 98.6%
Standard error 0.2 0.2 0.2 0.2 0.3
exposed to the risk 1347 4554 3109 2792 1761
5 years % 98% 97.1% 97.6% 97% 97.2%
Standard error 0.4 0.2 0.3 0.3 0.4
exposed to the risk 835 2886 1921 1800 1085
7 years % 97.1% 94.8% 96.4% 94.2% 95.9%
Standard error 0.6 0.5 0.4 0.6 0.6
exposed to the risk 243 869 556 556 312
10 years % 95.5% 91.4% 93.9% 90.6% 92.9%
Standard error 1.3 1.2 1.4 1.4 2.3
exposed to the risk 11 27 21 17 9
Log rank 0.011 0.009 0.125*
*R1E vs (T1E-R1E), no significant difference.
Key: RE (eligible for RIOP), R1nE (not eligible for RIOP), T1E (eligible for TARGIT
A) T1nE (not eligible for TARGIT A).
*Locoregional recurrence significantly more frequent in the case of over-
expression of Her2: only for patients not eligible for TARGIT A and RIOP
(selection of the most unfavorable cases).age ≤40 years (hazard ratio (HR) 2.03), margin invasion
(2.19), positive RHs (0.73) and Grade-3 tumors (HR 1.55)
[17]. In a study bringing together data from four trials,
van Nes et al. proposed a predictive index model with
three groups for the risk of local recurrence. However,
that study compared local recurrence after conservative
surgery and after mastectomy, and did not take account
of major forecast-relevant factors such as the SBR grade,
RH or vascular peri-tumor emboli [18]. These scores
(and others which are still being developed) ought to be
able to improve patient selection. However, only a sub-
group analysis of randomized trials can inform us if
these known “adverse” factors change the effectiveness
of radiotherapy.
The potential economic incentive of this method is
undeniable because intraoperative radiotherapy provides
the best possibility for treatment limited to a single day
in an outpatient setting. In our study and according to
the subgroups, the outlying percentages of patients who
could have benefited from TARGIT were 8% and 53%.
Hence, these patients could avoid external radiotherapy
or enjoy a reduction in the cost of treatment and the
journeys necessary to obtain treatment. In the UK, this
treatment would enable the waiting lists for postopera-
tive radiotherapy to be reduced, saving ≈ 23 million dol-
lars. In the United States, IPAS has been proposed as an
alternative to standard radiation among patients of the
most favorable American Society for Radiotherapy and
Oncology (ASTRO) group to limit the time and cost of
journeys for postoperative external radiotherapy [19].
The European Society for Radiotherapy and Oncology
(ESTRO) also propose a classification that enables selec-
tion of patients suitable for partial accelerated irradiation
of the breast [20]. A recent study of 59,396 patients
showed an increase in the use of partial accelerated ir-
radiation of the breast from 3.4% in 2003 to 12.8% in
2008 (p < 0.001) [21]. Indeed, the ICO 2012–03 Medico-
economic Study is underway in France to study the eco-
nomic incentive of this method.
Conclusion
TARGIT has potential advantages in terms of cost and
efficiency. Patient selection remains an important issue
but, given the prevalence of BC, a significant number of
treatments could be carried out in this way. Recent data
from a randomized trial are encouraging in terms of
Figure 2 Survival without locoregional recurrence: patients of the G3S cohort not eligible for the TARGIT A study as a function of the
HER2 status.
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follow-up program would be indispensable. The results
of our study suggest that almost 50% of T0–T2, N0 pa-
tients could be eligible for TARGIT with expected survival
without local recurrence in 5 years of 96.6–98.6%. Further
data from subgroup analyses may further improve patientTable 5 Comparison of survival without local recurrence of th
R2E
Number 356
3 years % 99.4%
Standard error 0.5
exposed to the risk 284
5 years % 98.6%
Standard error 0.7
exposed to the risk 132
7 years % 97.8%
Standard error 1.1
exposed to the risk 44
10 years % 92.6%
Standard error 5.1
exposed to the risk 12
12 years %
Standard error
exposed to the risk
Log rank
*R2E vs T2E-R2E, no significant difference.
Key: RE (eligible for RIOP), R2nE (not eligible for RIOP), T2E (eligible for TARGIT A) T2selection for intraoperative radiotherapy as the only radi-
ation treatment for early BC.
Consent
Written informed consent was obtained from the patient
for the publication of this report.e cohort 2
R2nE T2E T2nE T2E-R2E
4089 1509 2936 1153
96.3% 98.5% 95.4% 98.3%
0.3 0.3 0.4 0.4
3409 1235 2426 950
94% 96.6% 93.1% 96.1%
0.4 0.5 0.5 0.6
2411 804 1714 671
90.8% 94.1% 89.8% 93.4%
0.6 0.8 0.7 0.9
1950 465 1113 420
87.4% 91.9% 85.9% 91.4%
7 1.1 0.9 1.2
848 221 632 208
83.8% 82.2%
10 1.2
539 408
0.001 < 0.0001 0.084*
nE (not eligible for TARGIT A).
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